Member Info for Tim45

ACTIV-2 Phase 3 I think.

I was wrong - revealing interim results would undermine the credibility of the rich, complete data that will eventually follow.

Matterhorn - many thanks for your well-considered post. We have to be stocked and ready to treat breathless patients before the winter starts and presenting interim results are probably the only way that will happen.

This was discussed at length yesterday on the Reddit page. Very early small findings, no formal trial, no placebo, patent issues, etc. I wondered when it would appear here. If you want balanced discussion without the frantic responses on here at times, try the Reddit group.

Once again watching in the hope of mention of ACTIV-2 news but I fear it will be vaccines and their hiccups.

Watch it live at: https://www.pbs.org/newshour/health/watch-live-white-house-covid-19-response-team-holds-briefing-8

Matterhorn - many thanks for so clearly laying out this rationale, it all makes sense. I'm sure the large suitors have been doing their sums on volume and margins.

Thank you Spinnaker - a very realistic view.

My apologies if this has been discussed before but I am still unclear on the potential high volume manufacturing costs of SNG001.

If, as seems very possible from our Phase II results and the growing body of scientific evidence, inhaled interferon could one day be treating many millions of people worldwide at various stages of COVID infection and other respiratory problems.

I know that Synairgen has spoken of a cost of around £2,000 for a course of treatment (far less than the cost of hospitalisation) but what price might a large pharma be able to bring that price down to? What are the limiting costs on the ingredients of SNG001 and its manufacturing processes?

What are your thoughts?

Dr Faucci ... will definitely be on vaccines but possibly, one day, on treatments too ...

Live now: https://www.youtube.com/watch?v=8srnRO4nTJE

But accordining to the trial data, you do need to:

"Meet the protocol definition of being at "higher" risk of progression to severe COVID-19 (BRII-196/BRII-198, AZD7442 [IV])."

Interesting early research reported in 'Medical X Press', concluding with: " We believe that screening for these mutations in men who are admitted with severe disease and promptly treating them with interferon could prevent more deaths."

The article is at: https://medicalxpress.com/news/2021-03-rare-genetic-variant-younger-men.html

We also don't know if she received the placebo rather than SNG001.

Ooops ... sorry, here's the link to the video:

https://www.facebook.com/kuhospital/videos/349617149714151

Watch from 24m 52s to 28m 52s. Dr Mario Castro appeals for volunteers and mentions inhaled interferon as one of the six treatments.

Then a question is asked by 'Simon' about the inhaled interferon beta arm ... 'any resuls yet'? Dr Castro says it's blinded so nothing to report but he spoke positively about how it can be taken at home.

A very fast reply today from Prof. Philip Bath to my enquiry about whether 'Interferon' would be included in the PROTECT-CH trials. I didn't write as a shareholder or mention Synairgen or SNG001. No more revealing than we might expect but all helps to maintain a presence on their radar.

But as someone has already posted, by the time (May/June?) they even start PROTECT-CH trials, events with our HT, P3 results and ACTIV-2 may have moved us on from needing additional trial confirmation.

Dear Mr XXX,

Thanks but the government have not confirmed the drugs to be tested so we will have to see what they decide. I am aware of the interferon data, along with that for many other promising drugs, although there are many factors to be considered. Anyway, let's see what is decided.

All the best,

Philip Bath

Thanks Ferrari - good find. I especially liked: "The focus of treatment of COVID-19 has been on very ill hospitalized patients. Outpatients who do not require hospitalization are told to home quarantine with no effective treatment," from the Abstract.

Thanks Ferrari - a great find.
I particularly liked: "The focus of treatment of COVID-19 has been on very ill hospitalized patients. Outpatients who do not require hospitalization are told to home quarantine with no effective treatment." (From the abstract.)

No - it's for more of the AZD7442 mabs drug.

Miss_Nosaj - AZD7442 is one of the five other drugs (plus SNG001) on the ACTIV-2 trial. It is also down as 'Q4 2021' for the Estimated End Date.

Fruitsnveg - sorry, missed your question. No mention made of SNG001 or interferons.

You're right - the Phase 3 trial has to 'compete' with placebo patients who are receiving a better standard treatment than they would have during Phase 2 so it's reasonable to expect quite a bit less than less than 78%.